Bio-IT World January 13, 2026
Jacob Thaysen returned to the J.P. Morgan Healthcare Conference stage Tuesday with a message of momentum: Illumina is back to growth, and clinical sequencing is driving the train. In his third annual presentation as CEO, Thaysen unveiled preliminary fourth quarter results that exceeded expectations and introduced BioInsight, a new business unit aimed at accelerating drug discovery through AI-powered biological insights.
“I am proud of what the Illumina team delivered in 2025,” Thaysen said. “We remain focused on expanding the NGS ecosystem, supporting our customers and accelerating our growth into 26 and beyond.”
Q4 Beats Across the Board
The headlines came early: Illumina’s Q4 revenue grew 4% on a constant currency basis and 7% excluding China, with earnings per share between...
Today's Sponsors
Today's Sponsor